Showing results (191-200 of 366) with videos related to
Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2005
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumorsJosep Tabernero, Fredy Rojo, Irene Marimón, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialCarlota Costa, Miguel Angel Molina, Ana Drozdowskyj, et al.The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parametersSolange Peters, Walter Weder, Urania Dafni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung CancerMark M Awad, Patrick M Forde, Nicolas Girard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2024
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial UpdateAfshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, et al.Journal of Experimental & Clinical Cancer Research : CR|August 21, 2024
Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING studyElisabetta Petracci, Luigi Pasini, Milena Urbini, et al.Journal for Immunotherapy of Cancer|October 30, 2023
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trialCaicun Zhou, Minu K Srivastava, Hao Xu, et al.Cancers|April 27, 2024
Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid TumorsMaria-Josep Carreras, Berta Renedo-Miró, Carolina Valdivia, et al.The Lancet. Oncology|February 10, 2020
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarina C Garassino, Shirish Gadgeel, Emilio Esteban, et al.Pageof 37